Latest Information Update: 25 Sep 2006
At a glance
- Originator Novo Nordisk
- Class Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes insipidus
Most Recent Events
- 25 Sep 2006 Discontinued - Preclinical for Diabetes insipidus in Denmark (unspecified route)
- 14 Mar 2002 Preclinical trials in Diabetes insipidus in Denmark (unspecified route)